Zepbound
Tirzepatide · 5–15 mg/week
Eli Lilly
Dual GLP-1 / GIP receptor agonist — acts on two gut hormone receptors simultaneously for enhanced effect.
FDA Approved
November 2023
Last Updated
March 2026
Sources
5 peer-reviewed
Standard
YMYL / E-E-A-T
Medically reviewed by Dr. Sarah Mitchell, MD (Board-Certified Obesity Medicine) · Editorial Policy
How Zepbound Works
Dual GLP-1 / GIP receptor agonist — acts on two gut hormone receptors simultaneously for enhanced effect.
Dual Mechanism Advantage
Zepbound is a dual GLP-1/GIP receptor agonist, meaning it activates two appetite-regulating hormone pathways simultaneously. Standard GLP-1 drugs (like semaglutide) only target one receptor. The addition of GIP receptor activation enhances fat metabolism, provides complementary appetite suppression through different neural pathways, and may improve tolerability for some patients. This dual mechanism is why tirzepatide consistently outperforms single-agonist GLP-1 drugs in clinical trials.
Dosing & Administration
Titration Guidance
Zepbound uses a gradual dose escalation schedule over 20 weeks to max dose. Starting at 2.5 mg/week allows your body to adjust and minimizes GI side effects. Do not skip doses or increase faster than your physician recommends — this increases the risk of nausea, vomiting, and diarrhea. If side effects are severe at any dose, your doctor may extend the time at that dose before increasing.
Clinical Trial Results
SURMOUNT-1
202220.9% mean weight loss at 72 weeks (15mg dose) vs 3.1% placebo
SURMOUNT-2
202315.7% weight loss in T2DM population
Average Weight Loss: In clinical trials, patients taking Zepbound lost an average of 20–22% of their body weight. Individual results vary significantly — some patients lose considerably more or less than the average. Response depends on factors including baseline weight, diet, exercise, dose tolerated, and individual biology.
Side Effects
The most common side effects of Zepbound are gastrointestinal. They typically peak during dose escalation and improve over time as your body adjusts.
Contraindications
- • Personal/family history of MTC
- • MEN2 syndrome
- • Pregnancy
This is not a complete list of side effects. Serious but rare side effects include pancreatitis, gallbladder disease, and allergic reactions. If you experience severe abdominal pain, signs of allergic reaction, or any concerning symptoms, contact your healthcare provider immediately. Consult the full FDA prescribing information for a comprehensive list.
Cost & Insurance Coverage
Coverage Information
- • Commercial Insurance: Many plans cover Zepbound with prior authorization. Requirements typically include documentation of BMI ≥30 (or ≥27 with comorbidity) and, in some cases, documented failure of lifestyle modification.
- • Medicare Part D: Coverage is expanding. Coverage varies by plan and is improving in many states.
- • Manufacturer Savings: Eli Lilly offers savings cards that can significantly reduce out-of-pocket costs for eligible commercially insured patients.
Eligibility Criteria
Pros & Cons
Advantages
- ✓Highest published weight loss data of any approved drug (20–22%)
- ✓Dual mechanism (GLP-1 + GIP) for superior efficacy
- ✓FDA-approved for obesity
- ✓Better tolerated than semaglutide for many patients
Limitations
- ✗Newest on market — less long-term data
- ✗Very expensive without insurance
- ✗Supply constraints in 2024
- ✗GI side effects
Frequently Asked Questions
Quick Facts
Zepbound — From Our Blog
Medically reviewed articles to help you understand Zepbound (Tirzepatide).
Tirzepatide vs. Semaglutide at 72 Weeks: A Head-to-Head Analysis of the Data
The SURMOUNT and STEP trials provide the clearest comparison yet. Here's what 72 weeks of data actually shows about these two leading medications.
Finding Zepbound (Tirzepatide) Clinics Near You in 2026: A Practical Guide
Zepbound availability has improved but finding it can still be challenging. Here's how to find clinics, navigate insurance, and access tirzepatide.
Tirzepatide Nausea: Why It Happens and the Management Strategies That Actually Work
Nausea is the most common reason people quit tirzepatide early. Here's the mechanism behind it, a week-by-week timeline, and a tiered management approach that lets most patients push through.
Medical Disclaimer
This page provides general information about this medication for educational purposes only. It does not constitute medical advice and should not be used as a substitute for consultation with your healthcare provider. Always consult your physician or pharmacist before starting, changing, or stopping any medication. Drug pricing, insurance coverage, and clinical data may change after publication.